Last reviewed · How we verify
GBS-NN vaccine
At a glance
| Generic name | GBS-NN vaccine |
|---|---|
| Sponsor | Minervax ApS |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers
- A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women (PHASE2, PHASE3)
- Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants (PHASE1)
- Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women (PHASE2)
- Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine (PHASE1)
- GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age (PHASE2, PHASE3)
- Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV (PHASE2)
- Group B Streptococcus Vaccine in Healthy Females (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GBS-NN vaccine CI brief — competitive landscape report
- GBS-NN vaccine updates RSS · CI watch RSS
- Minervax ApS portfolio CI